<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="12607" end="12613" sStart="12564" offset="43" sid="r11.severe.j.0361" wn="1" wnkey="severe%5:00:00:intense:00" text="Three (10%) patients experienced severe neurological toxicity (1 with seizure, 2 with severe vertigo) but those complications resolved shortly after the completion of induction therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="1741" end="1747" sStart="null" offset="171" sid="r11.severe.j.0358" wn="1" wnkey="severe%5:00:00:intense:00" text="[ 20 21 22 23 ] Not only have remission and survival rates not been increased but the direct effect of growth factors on the untreated leukemia has led to severe toxic reactions and death." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="12670" end="12676" sStart="null" offset="106" sid="r11.severe.j.0362" wn="1" wnkey="severe%5:00:00:intense:00" text="Three (10%) patients experienced severe neurological toxicity (1 with seizure, 2 with severe vertigo) but those complications resolved shortly after the completion of induction therapy." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="6327" end="6333" sStart="null" offset="95" sid="r11.severe.j.0359" wn="1" wnkey="severe%5:00:00:intense:00" text="All patients received standard supportive care including blood component support for severe cytopenias as previously described." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="12129" end="12135" sStart="null" offset="59" sid="r11.severe.j.0360" wn="5" wnkey="severe%5:00:00:critical:03" text="All patients experienced fever in the setting of severe neutropenia." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="11361" end="11366" sStart="null" offset="0" sid="null" wn="1" wnkey="rapid%5:00:00:fast:01" text="Of the 13 patients who did not achieve CR, 1 received salvage chemotherapy, 2 received allogeneic BMT, and 10 died due to &lt;b&gt;rapid&lt;/b&gt; disease progression." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="15277" end="15281" sStart="null" offset="69" sid="r7.poor.j.0026" wn="4" wnkey="poor%3:00:02::" text="These two characteristics are among the most predictive of a poor outcome." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="15277" end="15281" sStart="null" offset="69" sid="r7.poor.j.0026" wn="5" wnkey="poor%5:00:00:insufficient:00" text="These two characteristics are among the most predictive of a poor outcome." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="15277" end="15281" sStart="null" offset="69" sid="r7.poor.j.0026" wn="5" wnkey="poor%5:00:00:insufficient:00" text="These two characteristics are among the most predictive of a poor outcome." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="15277" end="15281" sStart="null" offset="69" sid="r7.poor.j.0026" wn="4" wnkey="poor%3:00:02::" text="These two characteristics are among the most predictive of a poor outcome." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2407-2-12.anc" start="8866" end="8870" sStart="null" offset="0" sid="null" wn="3" wnkey="lose%2:37:00::" text="Only 28 patients are evaluable for induction response since 1 patient was &lt;b&gt;lost&lt;/b&gt; to follow-up shortly after receiving induction therapy (no evidence of persisting leukemia by the post-induction bone marrow biopsy)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="10917" end="10921" sStart="null" offset="109" sid="r10.high.j.0690" wn="1" wnkey="high%3:00:02::" text="Of the 13 patients who achieved CR, 6 patients received further consolidation chemotherapy (3 with high dose cytarabine, and 3 with intermediate dose cytarabine combined with daunorubicin, etoposide, or interleukin-2), and 6 patients received either allogeneic BMT or allogeneic PSCT." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="2885" end="2896" sStart="null" offset="4" sid="r11.combination.n.0792" wn="7" wnkey="combination%1:04:00::" text="The combination of timed sequential chemotherapy and hematopoietic growth factors allows for an initial cytoreductive course of chemotherapy before starting growth factors." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="4966" end="4971" sStart="null" offset="178" sid="r10.board.n.0486" wn="1" wnkey="board%1:14:00::" text="All patients gave signed informed consent and were treated on clinical protocols approved by the Cleveland Clinic Foundation's Institutional Review Board." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2407-2-12.anc" start="1339" end="1346" sStart="null" offset="78" sid="r11.benefit.n.0234" wn="2" wnkey="benefit%1:07:00::" text="[ 7 8 9 10 11 12 13 ] Several studies suggest a potential therapeutic benefit from administering hematopoietic growth factors before starting cytarabine-based chemotherapy." />
  </sentences>
</list>